|Articles|March 23, 2017
Medidata Platform Selected for Leukemia Trial
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML).
Advertisement
Medidata announced that The Leukemia & Lymphoma Society has selected Medidata’s Clinical Cloud platform to power its trial for acute myeloid leukemia (AML). Medidata is also incorporating its EDC, management and reporting solution, Medidata Rave, and its medical coding solution, Medidata Coder, to this trial.
Read the full release
Newsletter
Stay current in clinical research with Applied Clinical Trials, providing expert insights, regulatory updates, and practical strategies for successful clinical trial design and execution.
Advertisement
Related Content
Advertisement
Advertisement
Advertisement
Trending on Applied Clinical Trials Online
1
SCOPE Summit 2026: Where AI Is Making the Most Immediate Impact Across R&D
2
ACT Brief: FDA Capacity Strains Timelines, Sponsors Rethink Site Support, and Regulators Align on AI
3
Meeting Halfway: Co-Developing Frameworks for Seamless FSO to FSP Transitions
4
SCOPE Summit 2026: ESG Shifts From Reporting Exercise to Vendor Readiness Test in Clinical Operations
5